Versartis Grabs $21M

09:38 EST 16 Feb 2011 |

Mountain View, CA-based Versartis, the developer of protein drugs for endocrine disorders, said today it has raised $21 million in its Series B financing. The deal was led by New Leaf Venture Partners and Advent Venture Partners’ Advent Life Sciences fund, and included existing investors Index Ventures and Amunix. The company plans to use the [...]

Original Article: Versartis Grabs $21M


More From BioPortfolio on "Versartis Grabs $21M"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...